Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026064885> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2026064885 endingPage "306" @default.
- W2026064885 startingPage "301" @default.
- W2026064885 abstract "Cisplatin-based combination chemotherapy is the current standard chemotherapy for the management of advanced stage, epithelial ovarian cancer. However, correlation has been demonstrated previously between dose intensity and response for cisplatin, but not for the other cytotoxic drugs commonly used. We treated 46 consecutive, newly diagnosed patients following standard debulking laparotomy with cisplatin 60 mg m-2 every 2 weeks for a total of 8 cycles. Survival and toxicity were compared with those of a similar cohort of 24 consecutive, newly diagnosed patients treated with cisplatin 75 mg m-2 plus cyclophosphamide 600 mg m-2 every 4 weeks for 6 cycles, at the same institution immediately prior to the current cohort. The single-agent cisplatin cohort received a mean relative cisplatin-equivalent dose intensity of 1.43 compared with a received mean relative cisplatin-equivalent dose intensity of 0.88 in the combination chemotherapy cohort, a 62.5% increase in the cisplatin dose intensity. At 2 years, 69% of the patients receiving single-agent cisplatin were alive, compared with 38% of the group receiving the combination chemotherapy (P = 0.014). Alopecia (P < 0.00001) and myelosuppression (P < 0.0000001) were markedly less in the patient group receiving single-agent cisplatin. There was no significant difference in the incidence of neurotoxicity (P = 0.28) or nephrotoxicity (P = 0.38) between the two patient groups. In summary, relatively dose intensive, single-agent cisplatin given in a biweekly schedule for the first-line management of advanced stage, ovarian cancer produced a survival advantage compared with the previous combination cyclophosphamide/platinum combination chemotherapy. This novel therapy takes one-third less time to complete and causes fewer side effects than the current standard of combination cyclophosphamide and cisplatin." @default.
- W2026064885 created "2016-06-24" @default.
- W2026064885 creator A5025112205 @default.
- W2026064885 creator A5061164290 @default.
- W2026064885 creator A5068363543 @default.
- W2026064885 creator A5081802144 @default.
- W2026064885 date "1992-11-01" @default.
- W2026064885 modified "2023-09-25" @default.
- W2026064885 title "Novel, dose intensive, single-agent cisplatin in the first-line management of advanced stage ovarian cancer" @default.
- W2026064885 cites W1857437878 @default.
- W2026064885 cites W1917258958 @default.
- W2026064885 cites W1930308991 @default.
- W2026064885 cites W1997844432 @default.
- W2026064885 cites W2032528970 @default.
- W2026064885 cites W2032761343 @default.
- W2026064885 cites W2178925415 @default.
- W2026064885 cites W2418888487 @default.
- W2026064885 cites W7268927 @default.
- W2026064885 doi "https://doi.org/10.1046/j.1525-1438.1992.02060301.x" @default.
- W2026064885 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11576273" @default.
- W2026064885 hasPublicationYear "1992" @default.
- W2026064885 type Work @default.
- W2026064885 sameAs 2026064885 @default.
- W2026064885 citedByCount "8" @default.
- W2026064885 countsByYear W20260648852022 @default.
- W2026064885 crossrefType "journal-article" @default.
- W2026064885 hasAuthorship W2026064885A5025112205 @default.
- W2026064885 hasAuthorship W2026064885A5061164290 @default.
- W2026064885 hasAuthorship W2026064885A5068363543 @default.
- W2026064885 hasAuthorship W2026064885A5081802144 @default.
- W2026064885 hasConcept C121608353 @default.
- W2026064885 hasConcept C126322002 @default.
- W2026064885 hasConcept C126894567 @default.
- W2026064885 hasConcept C141071460 @default.
- W2026064885 hasConcept C143998085 @default.
- W2026064885 hasConcept C2776694085 @default.
- W2026064885 hasConcept C2776755627 @default.
- W2026064885 hasConcept C2778239845 @default.
- W2026064885 hasConcept C2780427987 @default.
- W2026064885 hasConcept C2781100745 @default.
- W2026064885 hasConcept C71924100 @default.
- W2026064885 hasConcept C72563966 @default.
- W2026064885 hasConcept C90924648 @default.
- W2026064885 hasConceptScore W2026064885C121608353 @default.
- W2026064885 hasConceptScore W2026064885C126322002 @default.
- W2026064885 hasConceptScore W2026064885C126894567 @default.
- W2026064885 hasConceptScore W2026064885C141071460 @default.
- W2026064885 hasConceptScore W2026064885C143998085 @default.
- W2026064885 hasConceptScore W2026064885C2776694085 @default.
- W2026064885 hasConceptScore W2026064885C2776755627 @default.
- W2026064885 hasConceptScore W2026064885C2778239845 @default.
- W2026064885 hasConceptScore W2026064885C2780427987 @default.
- W2026064885 hasConceptScore W2026064885C2781100745 @default.
- W2026064885 hasConceptScore W2026064885C71924100 @default.
- W2026064885 hasConceptScore W2026064885C72563966 @default.
- W2026064885 hasConceptScore W2026064885C90924648 @default.
- W2026064885 hasIssue "6" @default.
- W2026064885 hasLocation W20260648851 @default.
- W2026064885 hasLocation W20260648852 @default.
- W2026064885 hasOpenAccess W2026064885 @default.
- W2026064885 hasPrimaryLocation W20260648851 @default.
- W2026064885 hasRelatedWork W2062239485 @default.
- W2026064885 hasRelatedWork W2065800215 @default.
- W2026064885 hasRelatedWork W2133480631 @default.
- W2026064885 hasRelatedWork W2145130154 @default.
- W2026064885 hasRelatedWork W2328421677 @default.
- W2026064885 hasRelatedWork W2353260778 @default.
- W2026064885 hasRelatedWork W2444287241 @default.
- W2026064885 hasRelatedWork W3097676887 @default.
- W2026064885 hasRelatedWork W3100395499 @default.
- W2026064885 hasRelatedWork W59268075 @default.
- W2026064885 hasVolume "2" @default.
- W2026064885 isParatext "false" @default.
- W2026064885 isRetracted "false" @default.
- W2026064885 magId "2026064885" @default.
- W2026064885 workType "article" @default.